Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes - A paired donor kidney analysis

被引:591
作者
Meier-Kriesche, HU [1 ]
Kaplan, B [1 ]
机构
[1] Univ Florida, Dept Internal Med, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA
关键词
D O I
10.1097/00007890-200211270-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Waiting time on dialysis has bee shown to be associated with worse outcomes after living and cadaveric transplantation. To validate an quantify end-stage renal disease (ESRD) time as independent risk factor for kidney transplantation we compared the outcome of paired donor kidney destined to patients who had ESRD more than 2 year compared to patients who had ESRD less than months. Methods. We analyzed data available from the U. Renal Data System database between 1988 and 1998 by Kaplan-Meier estimates and Cox proportional hazard models to quantify the effect of ESRD time on paired cadaveric kidneys and on all cadaveric kidneys con pared to living-donated kidneys. Results. Five- and 10-year unadjusted graft survival rates were significantly worse in paired kidney recipients who had undergone more than 24 months of dialysis (58% and 29%, respectively) compared to paired kidney recipients who had undergone less than months of dialysis (78% and 63%, respectively; P < 0.001 each). Ten-year overall adjusted graft survival for cadaveric transplants was 69% for preemptive trans plants versus 39% for transplants after 24 months on dialysis. For living transplants, 10-year overall ad adjusted graft survival was 75% for preemptive trans plants versus 49% for transplants after 24 month on dialysis. Conclusions. ESRD time is arguably the strongest independent modifiable risk factor for renal trans plant outcomes. Part of the advantage of living-donor versus cadaveric-donor transplantation may be ex plained by waiting time. This effect is dominant enough that a cadaveric renal transplant recipient with an ESRD time less than 6 months has the equivalent graft survival of living donor transplant recipients who wait on dialysis for more than 2 years.
引用
收藏
页码:1377 / 1381
页数:5
相关论文
共 18 条
[1]   Pre-emptive kidney transplantation: the attractive alternative [J].
Asderakis, A ;
Augustine, T ;
Dyer, P ;
Short, C ;
Campbell, B ;
Parrott, NR ;
Johnson, RWG .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (07) :1799-1803
[2]  
Cecka J M, 2000, Clin Transpl, P1
[3]   Patient survival after renal transplantation: I. The impact of dialysis pre-transplant [J].
Cosio, FG ;
Alamir, A ;
Yim, S ;
Pesavento, TE ;
Falkenhain, ME ;
Henry, ML ;
Elkhammas, EA ;
Davies, EA ;
Bumgardner, GL ;
Ferguson, RM .
KIDNEY INTERNATIONAL, 1998, 53 (03) :767-772
[4]   The serum concentration of the advanced glycation end-product N-epsilon-(carboxymethyl)lysine is increased in uremia [J].
Degenhardt, TP ;
Grass, L ;
Reddy, S ;
Thorpe, SR ;
Diamandis, EP ;
Baynes, JW .
KIDNEY INTERNATIONAL, 1997, 52 (04) :1064-1067
[5]  
DESCAMPSLATSCHA B, 1994, SEMIN NEPHROL, V14, P253
[6]  
Friedlander MA, 1996, CLIN NEPHROL, V45, P379
[7]   INCREASED CARDIOVASCULAR RISK-FACTORS AND FEATURES OF ENDOTHELIAL ACTIVATION AND DYSFUNCTION IN DIALYZED UREMIC PATIENTS [J].
GRIS, JC ;
BRANGER, B ;
VECINA, F ;
ALSABADANI, B ;
FOURCADE, J ;
SCHVED, JF .
KIDNEY INTERNATIONAL, 1994, 46 (03) :807-813
[8]  
Hricik DE, 1996, CLIN TRANSPLANT, V10, P568
[9]  
KAUFMANN P, 1994, CLIN INVESTIGATOR, V72, P754
[10]  
Lowrie E G, 1998, Am J Kidney Dis, V32, pS105, DOI 10.1016/S0272-6386(98)70172-6